Robert Vonderheide
罗伯特·冯德海德
MD, DPhil
Director, Abramson Cancer Center; John H. Glick Abramson Cancer Center Professor艾布拉姆森癌症中心主任；约翰·格利克艾布拉姆森癌症中心教授
👥Biography 个人简介
Robert Vonderheide is Director of the University of Pennsylvania Abramson Cancer Center and a leading pioneer in cancer vaccine development and tumor immunology. His laboratory developed the first clinical evidence for KRAS-targeting cancer vaccines and CD40 agonist-based immunotherapy in pancreatic cancer, establishing immune activation strategies that synergize with mRNA vaccine platforms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KRAS-Specific Cancer Vaccines and Immune Targeting of Driver Mutations
Developed and clinically tested KRAS mutant peptide vaccines in pancreatic and lung cancer, demonstrating that oncogenic driver mutation-derived neoantigens can be immunogenic and that KRAS-specific T cell responses correlate with improved patient outcomes.
CD40 Agonist Immunotherapy for Pancreatic Cancer
Pioneered clinical development of CD40 agonist antibodies to activate antigen-presenting cells in the immunosuppressive PDAC tumor microenvironment, establishing combination strategies that prime immune responses exploitable by cancer vaccines.
mRNA-5671 KRAS Vaccine and Moderna Partnership
Collaborated on development of mRNA-5671, Moderna's mRNA vaccine encoding four KRAS oncogenic mutations, for phase 1 testing in KRAS-mutant pancreatic, colorectal, and lung cancers in combination with pembrolizumab.
Representative Works 代表性著作
CD40 agonists alter tumor stroma and show enhanced activity against pancreatic carcinoma when combined with gemcitabine
Clinical Cancer Research (2011)
First clinical demonstration that CD40 agonist antibody combined with chemotherapy can induce tumor regression in pancreatic cancer, establishing immunotherapy feasibility in PDAC and informing combination strategies with cancer vaccines.
T cell antigen discovery via trogocytosis
Nature Methods (2019)
Describes a novel platform for identifying T cell antigens including neoantigens and KRAS mutations recognized by T cells, directly enabling cancer vaccine target prioritization.
Immunity, immunoediting, and resistance in pancreatic ductal adenocarcinoma
Gastroenterology (2020)
Comprehensive review of immune evasion mechanisms in PDAC and strategies to overcome them, providing the conceptual framework for combining KRAS-targeting mRNA vaccines with checkpoint blockade and CD40 agonists.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 罗伯特·冯德海德 的研究动态
Follow Robert Vonderheide's research updates
留下邮箱，当我们发布与 Robert Vonderheide（University of Pennsylvania Abramson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment